Roche’s gene therapy drug Rugonersen boosts expression of the protein missing in the syndrome in mice and monkeys, but whether it works in people remains to be seen.
The post Promising preclinical results prompt Angelman therapy trial appeared first on Spectrum | Autism Research News.